Mounjaro®
Starting from £179.99/mo
Start journey Learn moreThere is no fixed time limit on how long you can stay on Mounjaro. The medicine is licensed in the UK for ongoing use as part of a weight management programme, and many people remain on it for well over a year. How long any individual continues is a clinical decision: your prescriber weighs the benefits you are seeing against any side effects, your personal health goals, and whether treatment is still the right fit. These are prescription-only medicines and every stage, from the first dose to any decision to stop, is reviewed by a clinician.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The question is a reasonable one, and it comes up often. A common assumption is that Mounjaro is a short course, something you take for three or six months and then stop once the weight is gone. That is not how it works. Tirzepatide's UK licence covers ongoing use alongside a reduced-calorie diet and increased physical activity, with no ceiling on duration built into the authorisation itself.
What actually governs length of treatment is clinical review. Mounjaro's licensed pathway asks prescribers to assess progress over time. NICE's recommendation, published in December 2024 and updated in September 2025, states that if a patient achieves less than 5% weight loss after six months at the highest tolerated dose, continuing treatment should be reconsidered. If it is working well, though, there is no clinical reason built into the guidance to impose a stop. You can read NICE's full appraisal of tirzepatide, including the continuation criteria, on the NICE website (TA1026).
The practical answer: how long you stay on Mounjaro depends on your goals, your response to treatment, your tolerability of side effects, and your prescriber's assessment at each review. That is a much more honest answer than a number in months.
This is where the decision gets genuinely complex. Tirzepatide works partly by reducing appetite through its action on GIP and GLP-1 receptors. When treatment ends, those signals return to baseline. Clinical evidence and the wider GLP-1 experience both show that weight regain is common after stopping, often beginning within weeks. That does not mean stopping is wrong, it means it warrants a plan.
For some people, the goal is to lose enough weight to make lasting lifestyle changes feel manageable, then taper off with a solid diet and activity routine in place. Others find that their weight-related health conditions (high blood pressure, sleep apnoea, elevated blood sugar) are the primary reason for continuing, and people researching specific conditions such as PCOS often find it useful to look at Mounjaro PCOS before and after accounts to understand how outcomes can vary. How long you stay on Mounjaro specifically for weight loss often comes down to which of these applies to you.
The NHS medicine information for tirzepatide reinforces that any decision to stop should involve your prescriber, not happen unilaterally. Discussing a tapering approach, or a planned review point, is better than simply stopping. You can find the patient-level information on the NHS tirzepatide medicines page.
Long-term treatment only makes sense when it is supervised. That means dose reviews, progress checks, and someone qualified watching for the things that matter: persistent side effects, any change in relevant health conditions, changes in medicines that interact with tirzepatide, and whether the benefit-to-risk balance still makes sense for you.
At nume, every repeat order goes through a fresh clinical review before it is approved. A real prescriber reads your updated information; no order rolls over automatically. That structure exists precisely because long-term prescribing demands ongoing scrutiny, not a set-and-forget approach.
If you are considering the cost side of staying on treatment longer term, our Mounjaro price comparison page sets out what the UK private market looks like and what an all-in price should include. Worth knowing before committing to any service for an extended period.
Progress on weight alone is not the only measure. When a prescriber considers whether to continue Mounjaro, they are likely thinking about several things at once: how much weight has been lost and whether it has plateaued; whether weight-related health conditions have improved; how well you are tolerating the medicine at the current dose; any new health information since the last review; and your own goals and preferences.
Questions like how long Mounjaro takes to work are related, early response (or its absence) can inform how long it makes sense to continue. Some people see significant change within the first eight to twelve weeks; others find the effect builds more gradually as the dose increases. Neither pattern tells you the total duration in advance.
If you are thinking about whether long-term treatment through a regulated online pharmacy is right for your situation, checking your eligibility is the first step. A prescriber can then give you a realistic picture based on your specific history.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.